Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1659617 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.36Day −37.90%Mkt cap $7M1Y −92.4%Off 52W high −92.7%Vol (1Y) 116.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,522 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest19.8% of sh out |
| Days to cover4.3d |
| 13F net flow (QoQ)+0.36% |
| Top-10 13F concentration99.7% |
| Next report (est.)2026-08-15 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$40.5M |
| ROE−256.0% |
| ROIC−303.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−58.9% |
| 1Y−92.4% |
| 3Y−99.4% |
| 5Y−99.9% |
| 10Y−100.0% |
| Since incept. (ann.)−60.5% |
Total return through 2026-07-29 · series begins 2016-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)116.1% |
| Ann. volatility (3Y)169.8% |
| Sharpe (1Y)−1.36 |
| Sharpe (3Y)−0.39 |
| Max drawdown (1Y)−92.4% |
| Max drawdown (3Y)−99.6% |
| Beta (3Y vs SPY)2.50 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| SABBY MANAGEMENT, LLC | 75,021 | $171,798 | 1.41% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 32,329 | $74,033 | 0.61% | +113.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 13,869 | $31,760 | 0.26% | new |
| HRT FINANCIAL LP | 13,739 | $31,000 | 0.26% | new |
| VANGUARD FIDUCIARY TRUST CO | 6,072 | $13,905 | 0.11% | new |
| Rockefeller Capital Management L.P. | 4,421 | $10,124 | 0.08% | +1928.0% |
| UBS Group AG | 3,409 | $7,807 | 0.06% | −41.9% |
| Tower Research Capital LLC (TRC) | 1,835 | $4,202 | 0.03% | +31.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | — | — | $0 | — |
| 2025-12-31 | 2026-03-18 | — | — | $0 | — |
| 2025-09-30 | 2025-11-13 | — | — | $0 | — |
| 2025-06-30 | 2025-08-12 | — | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-15 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
